BASELINE CHARACTERISTICS AND OUTCOME OF POPULATION WITH POLYCYSTIC KIDNEY DISEASE IN THE ICKD COHORT

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

BASELINE CHARACTERISTICS AND OUTCOME OF POPULATION WITH POLYCYSTIC KIDNEY DISEASE IN THE ICKD COHORT

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Vivek Kumar enigma165@yahoo.co.in Postgraduate Institute of Medical Education and Research, Chandigarh, India Nephrology Chandigarh India -

Co-author 2

Ashok Kumar Yadav mails2ashok@gmail.com Postgraduate Institute of Medical Education and Research, Chandigarh, India Experimental Medicine and Biotechnology Chandigarh India -

Co-author 3

Komal Sharma komusharma383@gmail.com Postgraduate Institute of Medical Education and Research, Chandigarh, India Nephrology Chandigarh India -

Co-author 4

Indrakshi Sharma indrakshisharma27@gmail.com Postgraduate Institute of Medical Education and Research, Chandigarh, India Nephrology Chandigarh India *

Co-author 5

Vivekanand Jha vjha@georgeinstitute.org.in George Institute for Global Health, New Delhi, India Global Health New Delhi India -

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Polycystic Kidney Disease (PKD) is a genetic disorder marked by multiple kidney cysts, often progressing to kidney failure and involving other organs. We present a descriptive analysis of baseline clinical features, disease history, complications, and outcomes of PKD patients from the Indian Chronic Kidney Disease (ICKD) cohort.

Methods

The ICKD study is a prospective, multicentric cohort study enrolling CKD patients with eGFR 15–60 mL/min/1.73 m² or >60 with proteinuria. We screened the ICKD database and identified 149 PKD patients out of 4306 enrolled subjects. A descriptive analysis was performed, covering baseline and clinical characteristics, comorbidities, medication usage, and follow-up events such as end-stage renal disease (ESRD), cardiovascular disease (CVD), and mortality.

Results

Out of 149 subjects, 94 males (63.9%) and 55 females (36.91%) with mean ± SD age was 46 ±11 years. Hypertension (69.8%) was the most common comorbidity, followed by renal stone disease (20.1%) and diabetes mellitus (14.1%) and CVD in 17 (11%). A significant proportion had a family history of hypertension (75.2%), diabetes (35.6%) and stroke (15.4%). 45 (30.2%) and 33 (22.1%) were current smokers and alcohol users. Baseline mean BMI was 23.4 ± 5.14 kg/m2 and eGFR was 53 ± 29 mL/min/1.73m2, which decreased to 22 ± 8 mL/min/1.73m2 at last follow-up. During the mean follow-up of 4.7 years, 60 (41%) subjects had eGFR decline of 50%, 22 (14%) patients developed ESRD, and 8 patients developed CVD events. Overall mortality was recorded in 15 (10%) subjects. Common medications included antihypertensives in 115 (77.1%) patients, calcium channel blockers in 60 (40.2%), and ACE inhibitors/ARBs in 28 (18.7%).

Conclusion

Baseline characteristics of the PKD study population reveal the burden of hypertension, progressive kidney dysfunction, and multisystem involvement in patients with PKD. Comprehensive management of comorbidities and complications is critical in improving outcomes for this patient population.

Kewords